Pharmaceuticals in Russia

Introduction

Pharmaceuticals in Russia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Russia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Russian pharmaceuticals market had total revenues of $14.8 billion in 2011, representing a compound annual growth rate (CAGR) of 16.1% between 2007 and 2011.

- 0

- The performance of the market is forecast to decelerate, with an anticipated CAGR of 11% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $24.9 billion by the end of 2016.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Russia

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Russia

Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Russia pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Russia economy

Key Questions Answered

What was the size of the Russia pharmaceuticals market by value in 2011?

What will be the size of the Russia pharmaceuticals market in 2016?

What factors are affecting the strength of competition in the Russia pharmaceuticals market?

How has the market performed over the last five years? SHOW LESS READ MORE >

Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Pharmstandard OJSC 20
Sanofi 23
Novartis AG 26
Bayer AG 29
Macroeconomic Indicators 33
Country Data 33
Appendix 35
Methodology 35
Industry associations 36
Related MarketLine research 36

LIST OF TABLES
Table 1: Russia pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Russia pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Russia pharmaceuticals market share: % share, by value, 2011 10
Table 4: Russia pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Pharmstandard OJSC: key facts 20
Table 6: Pharmstandard OJSC: key financials ($) 20
Table 7: Pharmstandard OJSC: key financials (RUB) 21
Table 8: Pharmstandard OJSC: key financial ratios 21
Table 9: Sanofi: key facts 23
Table 10: Sanofi: key financials ($) 24
Table 11: Sanofi: key financials (€) 24
Table 12: Sanofi: key financial ratios 24
Table 13: Novartis AG: key facts 26
Table 14: Novartis AG: key financials ($) 27
Table 15: Novartis AG: key financial ratios 27
Table 16: Bayer AG: key facts 29
Table 17: Bayer AG: key financials ($) 30
Table 18: Bayer AG: key financials (€) 30
Table 19: Bayer AG: key financial ratios 31
Table 20: Russia size of population (million), 2007–11 33
Table 21: Russia gdp (constant 2000 prices, $ billion), 2007–11 33
Table 22: Russia gdp (current prices, $ billion), 2007–11 33
Table 23: Russia inflation, 2007–11 34
Table 24: Russia consumer price index (absolute), 2007–11 34
Table 25: Russia exchange rate, 2007–11 34

LIST OF FIGURES
Figure 1: Russia pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Russia pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Russia pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Russia pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Russia, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Russia, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Russia, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011 19
Figure 11: Pharmstandard OJSC: revenues & profitability 21
Figure 12: Pharmstandard OJSC: assets & liabilities 22
Figure 13: Sanofi: revenues & profitability 25
Figure 14: Sanofi: assets & liabilities 25
Figure 15: Novartis AG: revenues & profitability 28
Figure 16: Novartis AG: assets & liabilities 28
Figure 17: Bayer AG: revenues & profitability 31
Figure 18: Bayer AG: assets & liabilities 32